Seventy-one patients with acute myeloid leukemia (AML), most of them (63/71) considered ineligible for conventional allogeneic hematopoietic stem cell transplantation (HSCT), were enrolled into a phase II study on reduced intensity myeloablative conditioning with fractionated 8 Gy total body irradiation (TBI) and fludarabine (120 mg/m 2 ). Patients received mobilized peripheral blood stem cells (n=68) or bone marrow (n=3) from siblings (n=39) or unrelated donors (n=32). Thirtysix patients were transplanted in complete remission (CR) and 35 with untreated or refractory disease (non-CR). Median patient age was 51 years (range, 20-66).
Introduction
For patients with acute myeloid leukemias (AML), allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most potent treatment options currently available. [1] [2] [3] [4] [5] [6] [7] Its anti-leukemic activity results in part from the powerful graft-versusleukemia (GvL) effect mediated by donor immune cells, [8] [9] [10] but is also attributed to myeloablative conditioning with high-dose chemo-radiotherapy. However, the gains in long-term disease control achieved with conventional allogeneic HSCT are to be weighed against considerable non-relapse mortality (NRM) secondary to treatmentrelated toxicity, severe graft-versus-host disease (GvHD) and infectious complications. [1] [2] [3] [4] [5] [6] [7] [11] [12] [13] [14] In a recent registry report, 2-year probabilities of NRM with standard approaches were 23-24%, 31-33%, and 46-48% for AML patients transplanted from sibling donors in first and second complete remission (CR) and with advanced disease, respectively, regardless of whether the stem cell source was bone marrow or peripheral blood.
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In order to overcome the high risk of fatal treatment-related complications, reduced intensity and nonmyeloablative conditioning regimens for allogeneic HSCT are currently being explored in various hematological malignancies including AML. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] These novel transplant strategies improve treatment safety and harness GvL effects rather than the eradication of the malignant clone by high-dose chemoradiotherapy. The regimens proposed, however, differ considerably in dose-intensity and myelosuppressive activity of cytotoxic agents. In a recent retrospective comparison of reduced intensity and even lower dose conditioning for allogeneic HSCT in patients with AML and high-risk myelodysplastic syndromes, higher dose intensity of the preparative regimen was shown to be relevant for long-term disease control though associated with increased morbidity and NRM. In the referenced study, both regimens consisted of combinations of fludarabine with cytostatic agents, i.e. melphalan or cytarabine/idarubicin. 25, 29 Earlier studies comparing total body irradiation (TBI)-based myeloablative regimens found similar dosing effects with an inverse relation between long-term anti-leukemic activity and NRM. 11, 13, 14, 30, 31 Thus, at least for allogeneic HSCT in AML, the optimal dose-intensity of preparative regimens for disease control at an acceptable rate of treatment-related lethal complications has not been determined.
We therefore evaluated reduced intensity myeloablative conditioning with 8 Gy TBI and fludarabine in AML patients considered ineligible for conventional conditioning. The results suggest that with this preparative regimen related and 
Supportive care
Infectious disease prophylaxis during the peritransplantation period consisted of pentamidine inhalation or administration of trimethoprim-sulfamethoxazole for Pneumocystis carinii prophylaxis, systemic antibiotics, fluconazole and acyclovir.
Patients underwent at least weekly surveillance testing for cytomegalovirus (CMV) pp65 antigen and/or polymerase chain reaction (PCR) for CMV DNA with preemptive ganciclovir therapy instituted for positive assays. Thirty-four patients received 5 µg/kg filgrastim subcutaneously daily beginning on day 6 after transplantation until an absolute neutrophil count (ANC) of 1.5 x 10 9 /L or higher was achieved for at least 3 consecutive days. All blood products were filtered and irradiated prior to transfusion.
Engraftment and toxicity
Neutrophil engraftment was defined as the first of 3 consecutive days with ANC ≥ 0.5 x 10 9 /L. Platelet engraftment was defined as the first day that the platelet count exceeded 50 x 10 9 /L without transfusion support. Hematopoietic chimerism was evaluated on bone marrow or peripheral blood cells by fluorescent in-situ hybridization studies in sex-mismatched cases for Y chromosome or analysis of DNA microsatellite polymorphisms by PCR as described. 37, 38 The sensitivity of chimerism analysis was 1% by FISH and ≤5% by PCR. 37, 38 Chimerism was assessed within 2 months of transplantation and subsequently at least every third month during the first two years. Regimen-related toxicity was graded according to the Common Toxicity Criteria Version 2.0 of the National Cancer Institute of the United States (http://ctep.cancer.gov/reporting/ctc.html).
Response, causes of death
CR prior to HSCT was defined by morphology as less than 5% blasts in marrow aspirates, the absence of blasts in the peripheral blood and of extramedullary manifestations, and ANC greater than 1.5 x 10 9 /L. Relapse was defined by standard morphologic criteria, reappearance of informative cytogenetic abnormalities or both.
CR post transplant was defined using the same criteria as above with donor cell engraftment.
Deaths after relapse were categorized as due to malignancy irrespective of any other causes. Early death was defined as death before day 15 after transplantation. Deaths in the absence of active AML, including early deaths, were categorized as NRM. Thus, the term NRM as used here determines the number of deaths with no relapse in relation to the number of patients evaluated in the study and is sometimes given as a percentage. Additionally, wherever the term mortality is used it relates to the study population.
Statistical analyses
The primary endpoints of this exploratory study were overall survival (OS), relapsefree survival (RFS) and the cumulative incidences of mortality from disease progression (MDP) and NRM. OS was calculated from the day of transplantation, with patients alive at the time of last follow-up being administratively censored. RFS was counted from the day of transplantation to relapse or death. Both, OS and RFS, were estimated by Kaplan and Meier curves. 39 Probabilities of relapse, MDP, GvHD, and NRM were calculated using cumulative incidence estimates to accommodate competing risks. 40 For statistical comparisons of group characteristics (donor type, ATG treatment, GvHD incidence), chi square analysis was used. Differences in estimated OS, RFS, relapse incidence, MDP and NRM between subgroups were evaluated using the log-rank test. The Cox proportional hazards regression model was used to assess the ability of patient covariates to predict probabilities of relapse. All were ineligible for conventional conditioning therapy because of reasons outlined above and in Table 1 . Thirty of these 63 patients fulfilled more than one of the exclusion criteria listed in Table 1 . Invasive fungal infection was the sole reason for applying reduced intensity conditioning according to the study protocol in 14 patients and a contributory criterion in an additional 13 patients.
The median patient age was 51 years (range, 20-66 years). Thirty-six patients were transplanted in CR (CR1: 23; CR2: 13) and 35 patients in non-CR (refractory disease: 27; untreated relapse: 7; untreated primary disease: 1). Pretransplant comorbidities as assessed by the adapted CCI were similar in the two patient groups regardless of whether or not age was included in the score. The proportions of patients transplanted in CR or in non-CR with a CCI score (including age) of 0 were 17% and 9%, with a CCI score of 1-2 66% and 82%, and with a CCI score of ≥3 17% and 9%, respectively. The median follow up of the surviving patients was 25.9 months (range, 3.7 -
months).
For This patient recovered with his own hematopoiesis without further treatment Engraftment data are summarized in Table 2 .
Regimen-related toxicity
Regimen-related toxicities are specified and graded in Table 3 . Grade III and IV toxicities were observed in 66% and 24%, respectively, of the total patient population.
In patients transplanted in CR, reversible grade III toxicities, predominately infections, mucositis and elevation of liver enzymes and bilirubin, occurred in 72% (26/36).
Seven patients in this group (19%) developed grade IV toxicities (3 reversible liver dysfunctions, 1 reversible infection and 3 fatal infections).
Similarly, grade III and IV toxicities were documented in 60% and 29%, respectively, of the patients transplanted in non-CR. Most common toxicities were infections, mucositis, elevation of liver enzymes and bilirubin, pulmonary and cardiac dysfunctions. Of the 10 patients with grade IV toxicities, 6 had severe liver toxicity (2 veno-occlusive diseases, both fatal) in combination with other adverse events (renal, pulmonary, cardiac or infectious), 1 developed fatal heart failure, 1 fatal pulmonary hemorrhage and 2 patients died from septic multiorgan failure.
GvHD
Cumulative incidences of acute GvHD for the total cohort are depicted in Figure 1 .
Grade II, III and IV acute GvHD occurred in 19%, 14% and 3%, respectively, of 37
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From evaluable patients transplanted from sibling donors. The corresponding rates for the 30 evaluable patients transplanted from unrelated donors were 17%, 13% and 7%, respectively. The cumulative incidence of grade II-IV GvHD was lower in patients transplanted in CR (23%) than in non-CR patients (50%; P<.05), although neither the percentage of unrelated donor transplants (39% and 51%, respectively) nor the percentage of patients receiving ATG with the preparative regimen (67% and 71%, respectively) differed significantly between the groups.
Of the 36 patients transplanted in CR, 34 were evaluable for chronic GvHD.
Among these patients, 17 developed chronic GvHD (11 limited and 6 extensive). Of those 17 CR patients with chronic GvHD, 10 had received ATG with the conditioning regimen. Because of the higher competing risks of NRM and MDP, the incidence of chronic GvHD tended to be lower in non-CR patients (25 evaluable patients, 2 limited and 8 extensive chronic GvHDs).
Disease response and relapse
Disease responses and outcomes after transplantation are shown in Table 2 . Of the 35 evaluable patients transplanted in CR, 6 patients suffered a relapse between days 68 and 868 after transplantation (cumulative incidence 17%). All three patients with late relapse (>1 year after transplantation) achieved a subsequent CR lasting 1301+, 1160+ and 1160+ days, respectively. Reinduction treatment consisted of cytoreductive therapy with cytarabine, additional blood stem cell transfusions from the original donor and subsequent treatment with granulocyte-macrophage colonystimulating factor (GM-CSF) in 2 patients 41 or a second transplant from the original donor in the third patient (conditioning therapy with fludarabine and melphalan).
Of the 35 non-CR patients, 32 were evaluable for disease response and relapse incidence, while 3 patients died early (days 9, 12 and 13, respectively).
Relapse of AML occurred in 16 of 32 patients between days 27 and 315 after transplantation (median, 84 days; cumulative incidence 50%). Two patients, one relapsing on day 155 and one on day 315, initially responded to donor lymphocyte and blood progenitor cell transfusions. One of these patients deceased 1583 days post transplant from progressive disease and one is alive with controlled disease at 684+ days. Four non-CR patients have remained in CR after transplantation.
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Non-relapse mortality
Notably, out of 36 patients transplanted in CR, only 3 patients (8%) had died from causes other than relapse at 1 year and the cumulative rate of NRM remained at 8% by 2 years and beyond. Two of the 3 patients died from infections while in CR on day 42 and 232, respectively. One 64 year old patient transplanted in CR2 with reduced renal function and invasive fungal infection deceased early on day 14 due to severe septicemia.
The cumulative rates of NRM for patients transplanted with active disease (non-CR) were 20% (n=7) at day 100 and 37% (n=13) at 1 and 2 years. In this group, patients deceased from causes other then progressive disease at a median of 78 days (range, 9-168) after transplantation ( Figure 2B ).
Relapse-free and overall survival
For patients transplanted in CR, RFS at 2 years was 78% (95% C.I., 63 -93%; Fig.   3B ). Since 3 of the 6 relapsing patients achieved another long lasting CR, OS at 2 years and beyond remained stable at 81% (95% C.I., 67 -95%; Fig. 3A ).
The high rates of MDP and NRM in non-CR patients resulted in a RFS and OS of only 16% (95% C.I., 3 -29%; Fig. 3B ) and 21% (95% C.I. 7 -36%; Fig. 3A) , respectively, at 2 years.
OS and RFS were similar in patients transplanted from sibling or unrelated donors ( Fig. 3C and D) .
Association among variables in univariate and Cox model analyses
Univariate analysis demonstrated that disease status before transplantation was significantly associated with the probabilities of relapse (P<.001), MDP (P<.001), NRM (P=.002), RFS (P<.001) and OS (P<.001). As another disease characteristic, unfavorable AML karyotype was associated with higher probabilities of relapse For
Discussion
Despite improvements in treatment safety, the corridor of favorable benefit / risk ratios for conventional allogeneic HSCT has remained narrow limiting indications to patients with a dismal disease prognosis who are young and otherwise medically fit. Thus, a majority of potential candidates in many hematological malignancies including AML are still being excluded from the procedure because of its inherent vital risks. The present trial was aimed at defining a transplant strategy in AML with an improved benefit / risk ratio, i. e. maintained anti-leukemic activity with reduced treatment-related morbidity and lethality, and the disease or remission status in which patients would benefit most.
The study was designed as a phase II trial in patients with AML considered to have a transplant indication, but not being eligible for allogeneic HSCT with conventionally dosed conditioning. Several reasons led us to evaluate this intermediate dose TBI-based preparative regimen. In a meta-analysis on the efficacy and safety of conventional myeloablative conditioning with cyclophosphamide in combinations with either busulfan or TBI, both types of regimens were shown to yield similar survival outcomes in the overall study population. 42 A nonsignificant 10%
higher survival rate after cyclophosphamide / TBI as compared to cyclophosphamide / busulfan in patients transplanted for AML reported in the referenced article is to be interpreted with caution. Notwithstanding, the 10-year overall and disease-free survival estimates for AML patients (mainly CR1) of 63% and 57%, respectively, demonstrate the potent anti-leukemic activity of TBI regimens. Likewise, a recent survey of the International Bone Marrow Transplant Registry (IBMTR) unveils a lower relapse risk for AML after allogeneic bone marrow transplantation with conventionally dosed TBI conditioning in comparison to busulfan / cyclophosphamide combinations. 43 Increasing the TBI dose from 12 to 15.75 Gy tended to reduce the relapse rate in patients transplanted for AML, but a significantly higher NRM during the first 6 months post transplant abolished potential survival advantages.
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Lowering the TBI dose to 9.9 Gy given along with cyclophosphamide appeared to be associated with a higher relapse rate while not reducing NRM. 44, 45 However, relapse rates may be dependent on not only total TBI dose, but also dose rate and fractionation schema. Along these lines, evidence of an improved benefit / risk ratio is provided by a recent series of unrelated donor transplants after conditioning with single exposure TBI of 5.5 Gy and cyclophosphamide. 27, 28 Further reducing the TBI dose to 2 Gy has yielded promising results with regard to engraftment and substantially lowered treatment-related toxicity. 20, 21 However, for patients with AML, it remains to be shown whether this minimal conditioning is sufficiently potent for longterm disease control. 23 With this background, we hypothesized that an intermediate patients (59%). Notwithstanding, rates of grade III/IV mucositis and hepatic toxicity (52% and 37%, respectively) were considerably higher than those reported for the 5.5 Gy (6-9% and 3-8%) 27,28 and the 2 Gy regimens (2% and 18-21%). 20, 21 Possibly, the risk of serious toxicity with the 8 Gy TBI dose could be reduced, e.g. by uniform TBI dose rate or by novel supportive approaches preventing severe mucositis. 46 However, in contrast to outcomes in patients transplanted with active and in most of our cases refractory disease, severe organ toxicities excluding infections were consistently reversible in CR patients (fatal organ toxicities: 0/36 CR patients versus 4/35 non-CR patients). Hence, although the regimen-related toxicity in CR patients was higher than that reported for the 2 Gy or 5.5 Gy regimens, it does appear to be manageable without translating into fatal events. Consequently, the ≥2-year cumulative incidence of NRM was only 8% in patients transplanted with CR and, thus, in the lower range reported for 2 Gy conditioning (1-year NRM 16 -20%) despite comparable pretransplant comorbidity scores.
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However, the favorable survival data in this group of patients are not only attributable to the lowered NRM, but also reflect the retained anti-leukemic activity of the study regimen and the improving immunocellular treatment options for relapses post transplant that can provide long lasting remissions and possibly cure. 41, 47 Finally, patients transplanted from siblings or unrelated donors had similar survival outcomes.
This observation would suggest that the favorable benefit / risk ratio of the study regimen equally applies to related and unrelated donor transplants with the improved donor recipient matching currently in use. Similar observations have recently been reported for allogeneic HSCT after myeloablative conditioning in acute lymphoblastic leukemia. 48 While our finding likely reflects small patient sample size, one might also speculate that particularly in the setting of reduced-intensity conditioning the use of unrelated donors potentially could be more efficacious secondary to an improved GvL effect.
The high rates of both NRM and relapse incidence for patients with active disease observed in the present study are comparable to those reported for conventional conditioning. CR1/CR2, complete remission 1 (n=22) or 2 (n=14); non-CR, patients with refractory disease (n=27), untreated relapse (n=7) or untreated primary disease (n=1). C and D, overall and relapse free survival was similar for patients transplanted from siblings (SIB) or volunteer unrelated donors (VUD) (CR-group: SIB n=22, VUD n=14; non-CR-group: SIB n=17, VUD n=18).
